Waldencast Acquisition Corp
$ 1.76
2.33%
24 Feb - close price
- Market Cap 232,491,000 USD
- Current Price $ 1.76
- High / Low $ 1.81 / 1.73
- Stock P/E N/A
- Book Value 5.91
- EPS -0.39
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.06 %
- 52 Week High 3.54
- 52 Week Low 1.45
About
Waldencast Acquisition Corp. The company is headquartered in White Plains, New York.
Analyst Target Price
$3.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-20 | 2025-12-30 | 2025-09-25 | 2025-05-13 | 2025-03-20 | 2024-11-20 | 2024-08-27 | 2024-05-21 | 2024-01-16 | 2023-11-09 | 2023-08-10 | 2023-04-26 |
| Reported EPS | 0 | -0.11 | -0.09 | -0.17 | -0.28 | -0.09 | -0.05 | -0.49 | -0.49 | 0 | 0.0733 | 0.025 |
| Estimated EPS | -0.11 | -0.11 | -0.07 | -0.038 | -0.0524 | -0.05 | -0.03 | -0.01 | -0.01 | -0.05 | 0.07 | -0.01 |
| Surprise | 0.11 | 0 | -0.02 | -0.132 | -0.2276 | -0.04 | -0.02 | -0.48 | -0.48 | 0.05 | 0.0033 | 0.035 |
| Surprise Percentage | 100% | 0% | -28.5714% | -347.3684% | -434.3511% | -80% | -66.6667% | -4800% | -4800% | 100% | 4.7143% | 350% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WALD
2026-02-03 20:00:37
Obagi Medical has launched a new Lip Therapy protocol featuring two innovative products: the AHA + PHA Smoothing Micro-Peel and the Soothe & Protect Lip Treatment SPF 30. This two-step regimen aims to gently resurface, hydrate, and protect the delicate skin on the lips, addressing concerns like texture, fine lines, and environmental damage. The dermatologist-tested duo is designed for nightly rejuvenation and daily protection, providing visible smoothing and improved lip health.
2026-01-10 17:32:00
Waldencast plc's stock has dropped 30% in the last month, contributing to a 49% decline over the past year. Despite this, the company's price-to-sales (P/S) ratio of 0.6x is similar to the Personal Products industry median of 0.8x. Analysts expect Waldencast's revenue growth of 4.6% next year to closely track the industry's 5.2% growth, suggesting that investors are comfortable with the current valuation and do not foresee significant changes in the near future.
2026-01-06 12:04:00
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. This investigation follows Waldencast's revised financial outlook for 2025, which significantly lowered previous guidance for net revenue growth and adjusted EBITDA, coupled with reported net losses driven by substantial impairment charges on its Obagi Medical and Milk Makeup brands. Following this news, Waldencast's share price dropped by 6.49%.
2026-01-01 10:00:00
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Waldencast's announcement of a revised financial outlook for 2025, significantly lowering revenue growth and EBITDA margin expectations, and reporting a net loss driven by impairment charges on its Obagi Medical and Milk Makeup brands, which caused a drop in share price. Investors impacted are encouraged to contact the firm regarding joining a potential class action.
2025-12-30 15:52:00
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of its investors. This investigation follows Waldencast's revised 2025 financial outlook, which projected significantly lower revenue growth and EBITDA margins than previously guided, alongside a reported net loss driven by substantial impairment charges. The news led to a 6.49% drop in Waldencast's Class A ordinary share price.
2025-12-27 12:08:47
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ:WALD) after a significant drop in its stock price. This follows Waldencast's revised financial outlook for 2025, which downgraded projected net revenue growth and adjusted EBITDA margin, and reported a substantial net loss due to impairment charges on its Obagi Medical and Milk Makeup brands. Investors are encouraged to contact Pomerantz LLP regarding their legal options.
